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Abstract: The pathology of Charcot-Marie-Tooth (CMT), a disease arising from mutations in different
genes, has been associated with an impairment of mitochondrial dynamics and axonal biology of
mitochondria. Mutations in ganglioside-induced differentiation-associated protein 1 (GDAP1) cause several
forms of CMT neuropathy, but the pathogenic mechanisms involved remain unclear. GDAP1 is an
outer mitochondrial membrane protein highly expressed in neurons. It has been proposed to play a
role in different aspects of mitochondrial physiology, including mitochondrial dynamics, oxidative
stress processes, and mitochondrial transport along the axons. Disruption of the mitochondrial
network in a neuroblastoma model of GDAP1-related CMT has been shown to decrease Ca2+
entry through the store-operated calcium entry (SOCE), which caused a failure in stimulation of
mitochondrial respiration. In this review, we summarize the different functions proposed for GDAP1
and focus on the consequences for Ca2+ homeostasis and mitochondrial energy production linked to
CMT disease caused by different GDAP1 mutations.
Keywords: GDAP1; recessive mutations; store operated calcium entry; mitochondrial location;
calcium regulated cell respiration
1. Introduction
Charcot-Marie-Tooth (CMT) disease is one of the most common inherited peripheral neuropathies,
with an overall population prevalence estimated at 10-28/100,000 in Europe [1]. It is characterized
by a degeneration of motor and sensory fibers that progresses slowly in a length-dependent manner.
In general terms, CMT disease is classified into demyelinating (CMT1) or axonal (CMT2) forms,
depending on the nerve conduction velocities in motor fibers of the median nerve [2]. More than
80 genes encoding proteins with very different functions have been linked to CMT disease and related
neuropathies [3]. One of them is ganglioside-induced differentiation-associated protein 1 (GDAP1), of which
more than 80 mutations have been found in CMT patients [4–6].
Mutations in GDAP1 show a wide range of severity and Mendelian heterogeneity [7], leading to
several forms of CMT disease including: recessive axonal (AR-CMT2K) [6]; recessive demyelinating
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(CMT4A) [5]; recessive with intermediate clinical features (CMTRIA) [8]; and dominant with axonal
features (CMT2K) [9,10].
GDAP1 is an outer mitochondrial membrane protein that is ubiquitously expressed with
predominant expression in nervous tissues [6]. In the peripheral nervous system, GDAP1 has
been found to be expressed mainly in axons rather than Schwann cells [11], but another study
also reported the presence of GDAP1 in myelinating Schwann cells [12]. This protein contains two
glutathione-S-transferase (GST) type domains [13] separated by an α-loop region, a C-proximal
hydrophobic domain, and a C-terminal transmembrane domain which is critical for its targeting to
the outer mitochondrial membrane [14]. GDAP1 has been proposed to play a role in a number of
mitochondrial functions, including mitochondrial dynamics [12,15–17], redox processes [18,19] or
mitochondrial transport, calcium homeostasis, and energy production [20,21].
Mitochondrial dysfunction has been shown to underlie numerous neurodegenerative diseases,
including Alzheimer´s (AD), Parkinson´s (PD), Huntington´s disease (HD), and also other forms of
CMT, such as CMT2A [22–25]. With this in mind, the implication of GDAP1 in CMT disease is not
surprising, since GDAP1 is involved in many mitochondrial functions. At the present, the molecular
pathogenesis of CMT disease caused by mutations in GDAP1 remains unclear. One reason may be
that the primary effect on mitochondria depends on the location of each mutation, and consequently
on the specific protein domain and function affected. However, a cell-specific effect of each of these
mutations cannot be excluded, given that GDAP1 is expressed in both peripheral neurons and in lower
levels in Schwann cells [6,18].
2. Proposed Roles of Ganglioside-Induced Differentiation-Associated Protein 1 (GDAP1) in
Mitochondrial Physiology
Different roles of GDAP1 have been proposed, most of which are related to mitochondrial
functions. Several studies have suggested an involvement of GDAP1 in mitochondrial dynamics.
Specifically, GDAP1 has been described as a fission factor whose activity depends on the fission factors
Drp1 and Fis1 [15]. Expression of human GDAP1 in Fis1 mutants in S. cerevisiae recovers cell size
and mitochondrial network morphology [26]. GDAP1 overexpression induced fragmentation of the
mitochondrial network, however, GDAP1 silencing enhanced the tubular aspect of mitochondria in
some studies [12,27] but not in others [20]. In this context, the effect of missense mutations in GDAP1
found in CMT patients on mitochondrial dynamics has been also addressed. Some studies have shown
that overexpression of recessive GDAP1 mutations was associated with a decrease in fission activity,
but not all mutants reduced fission activity to the same degree [15]. However, other overexpression
studies showed that these recessive mutations resulted in a fragmented mitochondrial network, with
no differences compared to the wild type protein, whose overexpression also caused mitochondrial
fragmentation [11,20]. Altogether, it is not clear how GDAP1 contributes to mitochondrial fission and
this suggests that GDAP1 must have another function rather than mitochondrial fission.
When GDAP1 was identified, phylogenetic and structural analysis suggested that GDAP1
belongs to a GST family [6,13], but early studies did not show any evidence of glutathione-dependent
activity [16,28]. However, a role of GDAP1 in regulation of cellular glutathione (GSH) content has
been shown, in which it confers a protective response against oxidative stress conditions [18,19,29].
Thus, mouse hippocampal neural cells selected as resistant to oxidative stress showed increased
GDAP1 levels and GDAP1 upregulation resulted in resistance against oxidative stress caused by GSH
depletion. [18]. Loss of GDAP1 also caused mild oxidative stress in mouse hippocampal neural cells
and in peripheral nerves in a mouse model of GDAP1-related CMT [18,19]. These studies suggest that
GDAP1 acts as a sensor of the reduced to oxidized glutathione ratio (GSH/GSSG) participating in
the release of an antioxidative response causing the recovery of GSH/GSSG. These results suggest a
possible role of oxidative stress and chronic inflammation in the pathogenesis of GDAP1-related CMT,
as shown to occur in other forms of CMT such as CMT1A [30] or CMT1C [31].
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Another relevant finding to understand the cellular role of GDAP1 is the fact that it localizes to
mitochondrial-associated membranes (MAMs) and interacts with trafficking-associated proteins [20].
MAMs are the place where physical communication between the endoplasmic reticulum (ER) and
mitochondria takes place, with both organelles 10–30 nm apart [32,33]. This finding suggests
participation of GDAP1 in the mitochondria-ER interface. Indeed, GDAP1 deficiency reduced contacts
between mitochondria and ER in neuroblastoma cells, and overexpression of GDAP1 in HeLa cells
increased co-localization between both organelles [20]. GDAP1 has also been involved in mitochondrial
transport within the cell, based on the interaction found between GDAP1 and β-tubulin, and the
trafficking-associated proteins, RAB6B and caytaxin [20]. The GDAP1 domain responsible for this
interaction is the α-loop, which is located between the two GST domains. In CMT mutations of this
domain, abnormal protein interactions between GDAP1 and the trafficking-associated proteins have
been found [20]. Anomalous distribution of the mitochondrial network has also been found in mouse
models lacking Gdap1 [34]. Together, these results suggest that a failure in mitochondrial movement
(toward the ER or other cell locations) that alters the distribution of the mitochondrial network may be
relevant to the pathogenesis of GDAP1-related CMT.
In addition to its role in mitochondrial functions, GDAP1 is also expressed in peroxisomes, where
it is involved in the regulation of peroxisomal morphology [17]. In N1E-115 cells, reduced levels of
GDAP1 led to elongated peroxisomes, while overexpression triggered peroxisomal fragmentation [17].
Patients suffering from CMT disease caused by mutations in GDAP1 show a wide range of clinical
manifestations, with the recessive forms of the disease (CMT4A and AR-CMT2) much more severe
than the dominant form (CMT2K) [7]. This fact points out that different molecular mechanisms may
underlie the pathology of CMT due to different mutations. It is possible that the clinical phenotype of
CMT disease caused by missense mutations depends on the specific protein domain affected and the
function associated with it. The variability of clinical features in these patients can also be explained by
the presence of modifier genes, whose influence on phenotype has been shown in several neurological
disorders [35,36]. Recently, juntophilin-1 has been described to act as a negative modifier of GDAP1 [37],
and the presence of the dominant GDAP1 p.R120W mutation along with the JPH1 p.R213P mutation in
a CMT patient led to a more severe form of the disease [37].
3. Role of Mitochondrial Traffic and Location in Charcot-Marie-Tooth (CMT) Disease
Mitochondria carry out many essential functions in the cell; they are the major cellular source
of ATP, obtained via oxidative phosphorylation, but also host several metabolic pathways, such
as the citric acid cycle, β-oxidation of fatty acids, and pyrimidine metabolism, among others [38].
Mitochondria are the main site where reactive oxygen species (ROS) are generated [39], and they are
also a key component of Ca2+ homeostasis in the cell, being able to modulate the dynamic of cytosolic
calcium signals by buffering Ca2+ flux from the ER or the plasma membrane [40–42]. Ca2+ flux between
the ER and mitochondria depends on the correct formation of MAMs [33]. Consequently, mitochondria
are fundamental for several biological processes, such as cell proliferation and necrosis or apoptotic
cell death [38].
Mitochondrial structure and localization are associated with their functionality. These two aspects
become more important in cells with high energy requirements such as neurons, particularly those
with long axons, in which mitochondrial positioning and turnover are more relevant due to the greater
energy demand that occurs in axonal terminals. Specifically, synaptic transmission [43] and vesicle
recycling [44] require larger amounts of energy. In sensory and motor neurons of the peripheral
nervous system (which are the cells affected by CMT disease), the regions with the highest energy
demands, and thus where mitochondria are concentrated, are: the distal region of the initial segment
of the axon; the nodes of Ranvier; and the neuromuscular junctions (in motor neurons) or sensory
end terminals (in sensory neurons) [45]. Interestingly, mitochondrial shape and localization are highly
regulated and depend on mitochondrial dynamics, motility, and tethering, all processes that have been
shown to be disrupted in GDAP1-related CMT models.
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Defects in axonal transport or abnormal mitochondrial distribution in axons have been described
in CMT arising from mutations in other genes, and other peripheral neuropathies involving mutations
in mitochondrial proteins or in proteins with roles in mitochondrial transport [46,47]. For example,
mutations in Mitofusin 2 (MFN2), which encodes an outer mitochondrial membrane protein involved
in mitochondrial fusion [48], are the primary cause of CMT2A, the most common form of the
autosomal dominant axonal CMT disease [22]. Dorsal root ganglion (DRG) neurons expressing
clinical MFN2 mutations showed impairment in transport of mitochondria along the axons [49].
An abnormal mitochondrial distribution was observed in a different mouse model of CMT2A, which
presented significant mitochondrial accumulation specifically in the distal axons [50]. Interestingly, the
accumulation of axonal mitochondria in the distal part of the sural nerve has also been observed in
CMT2A2 patients [51]. These results, together with a study that shows evidence for a role of MFN2
in mitochondrial transport through a direct interaction with the Miro/Milton complex [52], reinforce
the hypothesis that a failure in mitochondrial transport along the axons is the main pathological
mechanism involved in CMT2A2. Deficits in mitochondrial transport have been linked to other forms
of CMT disease. Mutations in HSPB1 and HSPB8 cause CMT2F and CMT2L respectively, and in both
situations a disruption of the cytoskeletal and axonal architecture, preventing mitochondrial movement
along the axons, has been found [53–56]. Taking all this together, axonal transport as a therapeutic
target in mitochondria-related CMT diseases has been proposed and it has been already addressed
in different models of CMT2 associated with HSPB1 mutations. Inhibition of histone deacetylase
6 (HDAC6), the major deacetylating enzyme of α-tubulin [57] has been tested in order to increase
the acetylation of α-tubulin and so facilitate the binding of molecular motor proteins (dynein and
kinesin family) to the microtubules [58]. Results obtained in several studies showed that the use of
different selective inhibitors of HDAC6 reverted mitochondrial transport defects in both motoneurons
obtained by induced pluripotent stem cells (iPSCs) differentiation from two patients with different
HPSB1 mutations [59] and in cultured DRG neurons expressing HSPB1 mutations [60,61]. Remarkably,
the restored motor and sensory problems have been observed in mutant HSPB1 mice in vivo [61].
4. Ca2+ Deregulation in GDAP1-Related CMT Disease
Impaired axonal mitochondrial movement and positioning found in different models of CMT
disease [20,49,55,56] may affect multiple mitochondrial functions. GDAP1 silencing in neuroblastoma
cells or genetic disruption in mice caused a similar change in Ca2+ homeostasis: a failure to activate the
store-operated calcium entry (SOCE) process [20,34], a cytosolic Ca2+ entry mechanism activated by a
decrease in ER- Ca2+ levels [62]. Activation of SOCE is a dynamic process; store depletion is sensed
by the ER stromal interaction molecule (STIM) proteins, STIM1 and STIM2, which oligomerize and
migrate to the ER regions juxtaposed to the plasma membrane [63,64]. At the same time, proteins
from the ORAI and transient receptor potential cation (TRPC) families which form the Ca2+ channel
accumulate in the plasma membrane directly opposite of the STIM clusters [65,66]. Interaction
between the channel proteins and the STIM clusters activates the store-operated calcium channels
(SOCs), allowing Ca2+ influx into the cytosol [67]. This process is highly regulated by Ca2+, with two
different mechanisms: a fast Ca2+-dependent inactivation mediated by Ca2+ near the mouth of the
channel; and a slow Ca2+-dependent inactivation mainly performed by mitochondria [68]. The failure
in SOCE found in GDAP1-deficient cells has been linked to a mislocalization of mitochondria at SOCE
sites (Figure 1). These cells showed a smaller number of mitochondria close to the plasma membrane
after SOCE activation, preventing proper mitochondrial Ca2+ uptake in the proximity of SOCs [20,21].
Mitochondrial Ca2+ uptake has been shown to facilitate SOCE by preventing its slow Ca2+-dependent
inactivation in several cell types [68–73].
Interestingly, missense mutations in GDAP1 seem to have different effects on Ca2+ homeostasis,
depending on their pattern of inheritance [21]. Overexpression of dominant GDAP1 mutations in
GDAP1-silenced cells resulted in an increase in SOCE activity above control levels, while the effect of
overexpression of recessive GDAP1 mutations depended on the location of the mutation in the protein.
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Cells carrying recessive GDAP1 mutations located in the GST or transmembrane domains showed no
failure in SOCE, but those located inside the α-loop domain (the region involved in protein-protein
interactions) mimicked the SOCE defect seen in GDAP1 deficiency [21]. Analysis of mitochondrial
distribution in cells expressing these mutations may explain these differences in SOCE. Mitochondria
carrying recessive GDAP1 mutations located in the α-loop domain did not relocate to the plasma
membrane under SOCE-activated conditions (Figure 1), a likely cause for SOCE impairment that is
similar to previous descriptions in GDAP1-deficient cells [20]. However, in cells expressing dominant
GDAP1 mutations, mitochondria were already in close proximity to the plasma membrane in basal
conditions [21]. This bias in basal mitochondrial distribution may be related to the increase in SOCE
activity found in these mutants, whose Ca2+-inactivation may be prevented by resident mitochondria
at the plasma membrane.
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Figure 1. Effects of ganglioside-induced differentiation-associated protein 1 (GDAP1) on mitochondrial
bioenergetic functions. (A) Interaction between GDAP1 and the trafficking proteins allows
mitochondria to be located close to the plasma membr ne after store-operate calc um entry (SOCE)
activation, preventing its Ca2+-dependent inactivation. Ca2+ uptake by mitochondria facilitates SOCE
but also regulates ATP production by oxidative phosphorylation. Ca2+-dependent regulation of
OXPHOS involves two main mechanisms (dotted red arrows); (i) Ca2+ ntry throug the mitochondrial
Ca2+ uniporter complex (MCUc) and the activation of dehydrogenases of the tricarboxylic acid
cycle (TCA), and (ii) activation of the neuronal Ca2+-dependent mitochondrial transporters of
aspartate/glutamate (Aralar) or ATP-Mg/Pi (SCaMC-3). Aralar activation increases Malate/Aspartate
shuttle (MAS) activity, ransferring reducing equiv ents from NADH to mitochondria and thereby
increasing pyruvate (Pyr) supply to mitochondria to enhance mitochondrial respiration. SCaMC-3
activation increases mitochondrial adenine nucleotide pool (solid and dotted black arrows);
(B) Mitochondrial movement might be affected by r cessive mutations located i the α-l op of GDAP1
causing the loss of interaction with trafficking proteins RAB6B and caytaxin which might affect the
proper mitochondrial localization at the subplasmalemmal microdomains and disturb SOCE activity
(red T bar). Subsequently, this will also impair mitochondrial bioenergetic functions by either decreasing
Ca2+ uptake by MCUc and activation of matrix dehydrogenases, and/or by decreasing the activation
of Ca2+-dependent mitochondrial transporters.
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The decrease in SOCE activity in recessive mutations in GDAP1 α-loop domain has been linked
to a decrease in ER- Ca2+ levels [21], consistent with the well-known function of SOCE in replenishing
the intracellular Ca2+ stores [74]. Lower ER-Ca2+ levels have also been observed in GDAP1-deficient
cells and in motor neurons from Gdap1-KO mice [34]. In neurons, ER- Ca2+ plays a relevant role
in synaptic activity, regulating several processes including synaptic plasticity [75], spontaneous
neurotransmitter release in synaptic boutons [76,77], and metabotropic glutamate receptor-dependent
synaptic transmission [78]. Disruption of ER- Ca2+ levels also leads to activation of ER stress coping
responses [79], such as the unfolded protein response (UPR), which activates apoptotic pathways
if ER- Ca2+ homeostasis cannot be restored [80]. These processes may be triggered by disturbed
Ca2+ homeostasis caused by the recessive mutations described above, but more studies are needed to
elucidate the real consequences of the decreased ER- Ca2+ levels in neurons affected by CMT disease.
In conclusion, although alterations in SOCE have been described in dominant GDAP1 mutations
and recessive mutations located in the α-loop domain, the mechanism of CMT pathogenesis of each
group of mutations seems to differ. These results suggest that decreased Ca2+ entry through SOCs
and lower ER- Ca2+ levels, probably due to a failure of SOCE Ca2+ uptake caused by mislocalized
mitochondria, may contribute to the pathogenesis of CMT patients carrying a recessive GDAP1
mutation inside the α-loop domain (Figure 1). On the other hand, dominant mutations may act
through a gain of function mechanism, which could be related to an increase in ROS production and
apoptosis, as reported previously [15]. Interestingly, an increase in SOCE activity has been found to be
detrimental in astrocytes in a mouse model of amyotrophic lateral sclerosis (ALS) [81], and in striatal
neurons in a model of HD [82].
5. Neuronal Store-Operated Calcium Entry (SOCE) and Its Role in Neurodegenerative Diseases
Ca2+ is a major second messenger in cells [83,84] of critical importance in neurons since it is a key
component of neurotransmission, synaptic plasticity, and gene transcription. Deregulation of Ca2+
homeostasis has been shown to be a common underlying mechanism of several major neurological
disorders including PD [85], HD [86], AD [87,88], or ALS [89]. Therefore, control of Ca2+ homeostasis
is essential for proper function of neurons. Neurons possess many different specialized Ca2+ channels
and a collection of Ca2+ handling proteins, several of them specific to neurons [90,91]. SOCE is the
main Ca2+ entry pathway in non-excitable cells [92], but its existence in neurons has been classically
debated due to the presence of other major Ca2+ influx pathways [93,94]. However, SOCE activity
has been found in different types of neurons both in the central [78,95–99] and peripheral nervous
system [100]. Neuronal SOCE has been shown to perform different functions in resting neurons:
refilling of Ca2+ stores [97]; control of spine morphology [101,102]; and regulation of neuronal gene
expression [103]. Moreover, an increasing number of studies have also proposed a role of SOCE in
neuronal synaptic activity by controlling Ca2+ dynamics [78,104–106] and different forms of synaptic
plasticity [75,107–109], including long term depression [95].
Considering all these functions, it is not surprising that disruption of neuronal SOCE has been
linked to major neurological disorders [110]. Different studies of familial AD caused by mutations
in presenilin genes reported general alterations in Ca2+ homeostasis, and specifically an impairment
in SOCE activity [101,111–114]. Additional evidence suggests that the molecular players of SOCE
may also be involved in the pathogenesis of AD. Changes in STIM1 and STIM2, the sensors of
intraluminal Ca2+ levels that transport information about Ca2+ load of the stores to channel proteins
at the plasma membrane [67], have been found in cases of sporadic [101] and familial AD [115].
Decreased STIM2 levels caused an impaired neuronal SOCE in two different mouse models of
familial AD, presenilin [101] and amyloid precursor protein knock-in (APPKI) mouse models [116],
leading to a disruption of SOCE-Ca2+/calmodulin-dependent protein kinase II (CaMKII) pathway
and finally, to mature spine loss. Importantly, overexpression of STIM2 in hippocampal neurons
rescued the downstream signaling cascade and dendritic spine morphology in both presenilin [101]
and APPKI mouse models [116]. The lack of STIM1 in differentiated neuroblastoma cells triggered
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a pathological increase in Ca2+ entry through L-type voltage-operated Ca2+ channels in response to
depolarization [115], in agreement with the modulating role of STIM1 on these channels [117,118].
Similarly, a failure in SOCE activation may also play a role in the pathogenesis of PD. The loss
of TRPC1 or STIM1, molecules involved in SOCE, has been linked to death of dopaminergic neurons
due to an increase in L-type Ca2+ currents [119,120]. Moreover, skin fibroblasts from idiopathic and
familial PD patients have been shown to have an impairment of SOCE activation not associated with
reduction in Orai1, TRPC1, STIM1 or STIM2 expression, and depleted ER-Ca2+ stores [121].
On the contrary, hyperactive SOCE has been linked to HD. Studies using the transgenic YAC128
HD mouse model found an enhanced SOCE in striatal medium spiny neurons (MSNs) [122–124],
which seems to compensate for an increase in Ca2+ leakage from the ER [122]. This abnormal activation
of SOCE may underlie the striatal synaptic loss found in YAC128 mice [122]. In this HD mouse model,
an increase in expression of the ER protein STIM2 has also recently been reported in cultured MSNs
and the striatum. Accordingly, downregulation of STIM2 rescued the loss of dendritic spines [122].
Modulation of all molecular players of SOCE may have a neuroprotective role not only in HD [125],
but also in other disorders where altered expression of these molecules has been found, such as
epilepsy and traumatic brain injury (TBI). STIM1 and STIM2 are upregulated in the hippocampus of
chronic epileptic mice and were found to be strongly expressed in hippocampal samples from a patient
suffering from medial temporal lobe epilepsy [126]. This highlights a role for SOCE in somehow
controlling neuronal network excitability, as proposed for dorsal horn neurons [127]. Expression
of these two ER proteins was also found to be upregulated after induction of TBI in two different
studies. Upregulation of STIM2, both in vitro and in vivo, triggered an increased SOCE, mitochondrial
Ca2+ overload and deregulation of mitochondrial functions, such as ROS production. Interestingly,
all these functions were recovered upon downregulation of STIM2 [128]. A different group showed
STIM1 upregulation in response to neuronal injury, finding that Stim1 knockdown improved neuronal
survival and reduced neuronal apoptosis after TBI [105].
All these studies suggest that SOCE may be a common mechanism involved in Ca2+ deregulation
in many neurological disorders, which may include CMT. However, the role and relevance of Ca2+
influx by SOCs in the neurons that are affected by CMT, i.e., the sensory and motor neurons of the
peripheral nervous system, is yet to be determined.
6. Impact of Ca2+ Deregulation on Mitochondrial Bioenergetics in GDAP1-CMT Model
Mitochondria use Ca2+ uptake and release to modulate cytosolic Ca2+ signals, thereby regulating
numerous processes in cells [42] including SOCE [129]. Mitochondrial Ca2+ handling is a highly
regulated process [130]. Permeability of the outer mitochondrial membrane is attributed to the
abundant expression of porins [131], whereas in the inner mitochondrial membrane, Ca2+ influx into
the matrix is mediated by the mitochondrial calcium uniporter (MCU) [132,133]. The properties of the
MCU are determined by several proteins that interact with it to form the MCU complex (MCUc) [42],
including the Ca2+ sensitivity modulators MICU1, MICU2, and MICU3 [134–136], the essential MCU
regulator (EMRE) [137], the dominant negative subunit MCUb [138] and the regulator (MCUR) [139].
Additionally, there are other routes of Ca2+ influx which are under debate [140]. The major Ca2+ efflux
pathway is the Na+/Ca2+ exchanger (NCLX) [141]. Ca2+ uptake by mitochondria not only serves as
a Ca2+ buffering system, but also as a pathway to regulate intrinsic functions, including the main
mitochondrial task: ATP production by oxidative phosphorylation [142,143].
Ca2+ influx through SOCs has been shown to stimulate mitochondrial respiration coupled
to ATP synthesis in human neuroblastoma cells [21]. Previous work in these cells found that
SOCE stimulation by muscarinic receptor activation induced glucose uptake by activation of AMP
kinase subsequent to CaMKKβ activation [144], which may provide respiratory substrates for
SOCE-stimulated respiration. Importantly, SOCE-induced upregulation of mitochondrial respiration
is impaired by GDAP1 deficiency or by the presence of recessive GDAP1 mutations located inside the
α-loop domain in these cells [21].
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In excitable cells, the role of Ca2+ in tuning energy supply to demand has long been
known [145–147]. Ca2+ regulates ATP homeostasis both by increasing ATP consumption via activation
of several ATP-dependent processes, and by promoting ATP synthesis through activation of
mitochondrial dehydrogenases and direct stimulation of oxidative phosphorylation (OXPHOS) [148].
Neuroblastoma cell experiments using BAPTA-AM, a calcium chelator that prevents Ca2+ signaling
but not changes in workload [149], showed that Ca2+ signaling itself is needed to couple SOCE activity
to mitochondrial respiration [21].
Ca2+-dependent regulation of OXPHOS involves two main mechanisms (Figure 1). On the
one hand, Ca2+ entry into mitochondria through the MCUc [42] is known to activate different
enzymes in the matrix, including the citric acid dehydrogenases: isocitrate dehydrogenase and
α-ketoglutarate dehydrogenase, which directly bind Ca2+; and pyruvate dehydrogenase, which is
activated by Ca2+-sensitive phosphatase activity [150,151]. Matrix Ca2+ has also been proposed to
regulate both F1-F0ATPase activity, by reducing its resistance to ATP production, and some other
respiratory complexes [148,151]. The second mechanism involved in Ca2+-dependent regulation
of OXPHOS does not require Ca2+ entry into mitochondria, rather it depends on the activity of
calcium binding mitochondrial carriers (CaMCs) (Figure 1). Two groups of carriers form this family:
the aspartate-glutamate carriers (AGC); and the ATP-Mg/Pi carriers, also named SCaMC (for short
CaMC) [152–156]. Both types of CaMCs are characterized by the presence of EF-hand domains that
are oriented toward the intermembrane space and activated by cytosolic Ca2+ [157–160]; they both
function along with the MCU to decode the Ca2+ signal into a mitochondrial response.
In neuroblastoma cells, a rise of mitochondrial Ca2+ levels has been shown upon SOCE activation,
suggesting that both mechanisms, matrix and extramitochondrial Ca2+ signaling pathways, may be
implied to boost respiration [21]. Establishing which of these mechanisms is involved will aid in
identifying potential targets in GDAP1-related CMT diseases that may lead to a failure in mitochondrial
energy metabolism. Disruption of any of these mechanisms has been found to impair mitochondrial
bioenergetics in different cell types. For example, in cardiomyocytes, the MCU selectively mediates
acute mitochondrial Ca2+ loading to augment ATP production [161,162], and a lack of MCU in skeletal
muscle led to an impaired oxidative metabolism and a shift toward fatty acid metabolism [163,164].
On the other hand, in cortical neurons Aralar/AGC1 is required to adjust coupled respiration to ATP
demand under different workloads by providing pyruvate to mitochondria [147,149,165]. These results
indicate that each Ca2+-dependent regulation of OXPHOS may have different relevance depending on
cell type.
In conclusion, in neuroblastoma cell lines, SOCE deregulation affects cellular respiration in cells
carrying recessive GDAP1 mutations inside the α-loop domain (Figure 1) [21]. This suggests that a
failure in mitochondrial bioenergetics may contribute to the molecular pathogenesis of CMT disease
caused by these mutations. It will be interesting to know whether a similar deregulation and failure in
mitochondrial bioenergetics occurs in sensory and motor neurons in other types of GDAP1-related
and other mouse models of CMT disease.
7. Concluding Remarks
An impairment of axonal mitochondrial transport has been proposed to underlie the pathology of
CMT due to mutations in different genes, as CMT2A2 [49], CMT2F [55,56], and CMT2L [53]. Studies
of the effect of different CMT mutations in GDAP1 showed changes in mitochondrial dynamics
and distribution within the cell and may be across the axon, leading to a general disruption of the
mitochondrial network [12,15,16,20,21]. As alteration of a mitochondrial process can also affect other
cellular functions, it can be challenging to identify the true cause of the pathology. A failure in
Ca2+ homeostasis as a consequence of mitochondrial mislocalization has been found in cells carrying
dominant GDAP1 mutations and recessive mutations located inside the α-loop domain (Figure 1),
with an associated augmentation or decrease of SOCE activity, respectively [21]. Interestingly, no Ca2+
alterations have been found in recessive mutations located outside the α-loop domain of GDAP1,
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which may act by a completely different mechanism. Recessive GDAP1 mutations inside the α-loop
domain cause a failure in stimulation of mitochondrial respiration associated with an impairment
in SOCE activity (Figure 1) [21], but this may also take place in other GDAP1-related CMT diseases.
For example, the prolonged elevated ROS production described in dominant mutations [15] may
trigger permanent damage to mitochondria, leading to an impairment in bioenergetics [166].
These results suggest that a failure in mitochondrial control of Ca2+ entry by SOCs could be a
possible mechanism underlying the pathology of GDAP1-related CMT, although additional defects in
other Ca2+ entry mechanisms, such as voltage gated Ca2+ channels, cannot be excluded, particularly
those in neuromuscular junctions [167–170]. More studies are necessary to identify which Ca2+
mechanisms are altered in the affected neurons of GDAP1-related CMT patients and Gdap1 mouse
models in comparison with other mouse models of CMT.
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